Epistem Limited

disease & therapeutic research models

Inflammatory Bowel Disease

GI Toxicity and Mucositis

Immune Cell Assays

Rheumatoid Arthritis

services

Gene Expression Analysis

Histology and IHC Services

Laser Capture Microdissection

Analytical Services

Plucked Hair Analysis

Spotlight On...

Genome-wide identiﬁcation of differentially methylated promoters and …
Researchers have demonstrated differential methylation of promoters and enhancers between responders and non-responders prior to treatment with PD-1…
Biomarker function of HMGA2 in ultraviolet-induced skin cancer development
A recent study discovered that HMGA2 is highly expressed in human cutaneous squamous cell carcinoma (SCC) cell lines and primary SCC tumours, but not…
The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
A recent study published in Nature sheds light on the role of the gut microbiome in switching mutant p53 from tumour-suppressive to…
Lgr5+ telocytes are a signalling source at the intestinal villus tip
A recent study utilising spatially-resolved transcriptomics and laser capture microdissection has discovered that Lgr5+ telocytes act as a signalling…
CD47 is a negative regulator of intestinal epithelial cell self-renewal …
Scientists have demonstrated that epithelial cell CD47 expression in the colon is strongly induced in patients with ulcerative colitis and Crohn's…

Announcements

ANNOUNCING:
RECRUITING: SENIOR OR PRINCIPAL SCIENTIST - FIBROSIS MODELS
Epistem are on the lookout for an individual with a strong background in fibrotic remodeling with industry experience or 5 years post-doc
NEWS: Epistem licence Hubrecht Organoid Technology to expand preclinical toxicology service portfolio
2019-07-15
Epistem Limited has announced the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB)…
NEWS: 10 Years GCLP Accreditation at Epistem
2019-01-11
We are pleased to announce the successful GCLP re-accreditation of our laboratories.

© 2018, 2020 Epistem Ltd.

site map | privacy policy | terms of use | contact us

Call us on +44 (0)161 850 7600 or email info@epistem.co.uk

Accelerating Drug Development with Innovative Services

This site uses cookies for tracking and statistical purposes. Please read our privacy policy for more information.

Don't show this again